Characterization of CHK-336, A First-in-Class, Liver-Targeted, Small-Molecule Lactate Dehydrogenase Inhibitor for Hyperoxaluria Treatment.
Jennifer H Cox, Marc-Olivier Boily, Alexandre Caron...
https://pubmed.ncbi.nlm.nih.gov/40193200/Actively Recruiting
Led by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · Updated on 2025-12-24
28
Participants Needed
18
Research Sites
4 weeks
Total Duration
Researchers are evaluating DCR-PHXC in individuals with Primary Hyperoxaluria Type 1 PH1 who have severe kidney impairment, including those on dialysis. This Phase 2 open-label study aims to assess the safety and effectiveness of DCR-PHXC in this specific patient group, which includes adults, children, and infants under 6 years old. The study is conducted by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, and focuses on participants with a confirmed PH1 diagnosis and significant kidney function decline. Participants will receive monthly subcutaneous injections of DCR-PHXC, with dosing schedules adjusted according to age and weight. After a screening period of up to 35 days, monthly dosing visits will continue through Day 180. Those completing the initial treatment phase may enter an extended follow-up period of up to five years or until the drug becomes commercially available. During this extension, dosing may be administered at home by participants, caregivers, or home health nurses with training. Throughout the study, participants will attend regular clinic visits for dosing and assessment. Researchers will monitor safety by tracking incidence of adverse events over 180 days. They will also evaluate changes in plasma oxalate levels, dialysis frequency and duration, and pharmacokinetics of DCR-PHXC. The total study duration can extend up to 10 years including the extended follow-up phase. Participants health and treatment compliance will be regularly assessed to understand the long-term effects of DCR-PHXC.
CONDITIONS
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
N
Novo Nordisk
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | DCR-PHXC (investigational) | Current standard care |
|---|---|---|
| What it is | A monthly RNA interference (RNAi) therapeutic targeting hepatic glycolate oxidase, given by subcutaneous injection and evaluated as an experimental treatment for PH1 in patients with end-stage renal disease. | Intensive dialysis (hemodialysis or peritoneal dialysis), continued until kidney transplantation is feasible, is the current standard therapy for PH1 patients with end-stage renal disease, typically along with supportive treatments. |
| Role in the trial | Evaluated as a novel investigational treatment for reducing oxalate burden in PH1 patients with ESRD. | Current practice for these patients is focused on maintaining metabolic stability and removing oxalate by regular dialysis until transplantation becomes possible. |
| Primary use | Investigational therapy intended to lower plasma oxalate concentrations and reduce oxalate-related morbidity. | Dialysis is used to control systemic oxalate levels and manage symptoms until transplantation can be pursued. |
| How it is given or performed | Administered as a monthly subcutaneous injection during the entire study period. | Patients undergo routine hemodialysis or peritoneal dialysis several times per week, according to clinical need, with supportive medications as required. |
| Evidence status | Efficacy and safety are being actively studied; no published results from this trial are yet available. | Dialysis is an established treatment with well-known risks and benefits, but is not curative and usually requires transition to transplantation. |
| Important limitations | DCR-PHXC's effectiveness and long-term safety are not yet established, and the drug remains investigational; only selected patients are enrolled and data are awaited. | Dialysis is burdensome and may not fully prevent systemic oxalosis complications; transplantation may eventually be required for long-term control. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 35 days
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 6 months
Participants receive monthly doses of DCR-PHXC for 180 days to evaluate safety and efficacy.
Monthly visits for dosing through Day 180
Duration - Up to 5 years
Participants who complete the initial 180-day treatment continue receiving DCR-PHXC with visits every 3 months for up to 5 years or until the drug becomes commercially available. Participants or caregivers may be trained for at-home administration or receive assistance from home health nurses.
Quarterly visits for dosing and monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Jennifer H Cox, Marc-Olivier Boily, Alexandre Caron...
https://pubmed.ncbi.nlm.nih.gov/40193200/Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Lead Sponsor